FOR IMMEDIATE RELEASE

Neomatrix and 4basebio Announce Publication in Journal for ImmunoTherapy of Cancer Demonstrating Potent Personalized Cancer Vaccine Responses Using Synthetic DNA Platform

We are proud to announce the publication of our latest work in the Journal for ImmunoTherapy of Cancer (JITC):
“Synthetic DNA vaccine platform elicits potent immunity where electroporated naked-mRNA is non-immunogenic”.

This study represents an important milestone for **NeoMatrix** and our collaboration with **4basebio**, demonstrating the potential of synthetic hairpin DNA (hpDNA) as a next-generation platform for personalized cancer vaccines.

Our data show that synthetic hpDNA delivered by electroporation induces:

- Strong neoantigen-specific CD8+ and CD4+ T-cell responses
- Durable immune memory
- Anti-tumor and anti-metastatic activity
- Synergy with immune checkpoint inhibitors

Importantly, the work highlights how delivery context and innate immune activation are critical determinants of vaccine immunogenicity.
What makes this particularly exciting is the use of fully synthetic, cell-free DNA manufacturing technology — enabling a scalable, rapid and highly pure platform potentially suited for individualized cancer immunotherapy.

We believe synthetic DNA represents a cutting-edge enabling technology for the future of precision medicine.

Neomatrix s.r.l.
Via di Castel Romano n. 100
00128 Roma
C.F./P.IVA 15698291000
Pec: neomatrixsrl@pec.it